Drug-induced nightmares


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

According to modern concepts, nightmares are classified as parasomnias. The use of various drugs is one of the important factors inducing their appearance; in this case nightmares are called drug-induced nightmares. The incidence of drug-induced nightmares has not been precisely established, but it can reach 59% against the background of use of certain drugs (for example, mefloquine). The mechanism of development of drug-induced nightmares is most often related to their effect on various receptors and neurotransmitter systems: adrenergic, dopaminergic and cholinergic. Among the different classes of drugs, antidepressants, antiparkinsonian drugs, analgesics, drugs used to treat cardiovascular diseases and some others are more often associated with the development of nightmares. The tactics of managing patients with drug-induced nightmares involves identifying and canceling a drug that induced a nightmare or reducing its dosage, as well as prescribing this drug in the morning if possible. Prevention of drug-induced nightmares is based on the adherence to the principles of rational pharmacotherapy, especially on the avoidance of exceeding the allowable dosage of drugs.

Texto integral

Acesso é fechado

Sobre autores

T. Ostroumova

Sechenov First Moscow State Medical University (Sechenov University)

O. Ostroumova

Sechenov First Moscow State Medical University (Sechenov University); Pirogov Russian National Research Medical University, Russian Gerontological Research and Clinical Center

Email: ostroumova.olga@mail.ru
MD, Professor at the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases; Head of the Laboratory of Clinical Pharmacology and Pharmacotherapy

A. Kochetkov

Pirogov Russian National Research Medical University, Russian Gerontological Research and Clinical Center

A. Pereverzev

Pirogov Russian National Research Medical University, Russian Gerontological Research and Clinical Center

Bibliografia

  1. Sateia M.J. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146(5):1387-94. doi: 10.1378/chest.14-0970.
  2. Полуэктов М.Г. Диагностика и лечение расстройств сна. М. 2016;193-97.
  3. Aurora R.N., Zak R.S., Auerbach S.H., et al. Best practice guide for the treatment of nightmare disorder in adults. J. Clin Sleep Med. 2010;6(4):389-401.
  4. Остроумова О.Д., Исаев РИ., Переверзев А.П. Лекарственно-индуцированная инсомния у пациентов пожилого и старческого возраста. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(8):142-52.
  5. Hasler B.P., Germain A. Correlates and treatments of nightmares in adults. Sleep Med Clin. 2009;4(4):507-17. Doi: 10.1016/j. jsmc.2009.07.012
  6. Sandman N., Valli K., Kronholm E., et al. Nightmares: risk factors among the Finnish general adult population. Sleep. 2015;38(4):507-14. doi: 10.5665/sleep.4560.
  7. Nagy T., Salavecz G., Simor P., et al. Frequent nightmares are associated with blunted cortisol awakening response in women. Physiol Behav. 2015;147:233-37. Doi: 10.1016/j. physbeh.2015.05.001.
  8. Nielsen T. Nightmares associated with the eveningness chronotype. J. Biol Rhythms. 2010;25(1):53-62. doi: 10.1177/0748730409351677.
  9. Agargun M.Y, Mustafa G., Savas C.A.,. et al. Nightmares and serum cholesterol level: a preliminary report. J Nerv Ment Dis. 2005;50(6):361-64. doi: 10.1177/070674370505000613.
  10. Pagel J.F., Helfter P. Drug induced nightmares -an etiology based review. Hum Psychopharmacol. 2003;18(1):59-67. doi: 10.1002/hup.465.
  11. Ковальзон В.М. Нейрофизиология и нейрохимия сна. В. кн.: Сомнология и медицина сна. Национальное руководство памяти А.М. Вейна и Я.И. Левина. Под ред. М.Г. Полуэктова. М.: Медфорум. 2016.
  12. Литвиненко И.В. Нарушения сна и памяти, ацетилхолин при некоторых нейроде-генеративных заболеваниях, применение пролонгированной формы галантамина. Неврология, нейропсихиатрия, психосоматика. 2012;4(2):100-5.
  13. Steriade M. Brain electrical activity and sensory processing during waking and sleep states. In: Kryger M.H., Roth T., Dement W.C. (Eds.) Principles and practice of sleep medicine (5th ed.). St. Louis, MO: Elsevier Saunders. 2005. P. 101-19. doi: 10.1016/B0-72-160797-7/50016-1.
  14. Дамулин И.В., Яхно Н.Н. Болезнь Альцгеймера и сосудистая деменция. М., 2002.
  15. Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте. М., 2005.
  16. Conant J., Engler R., Janowsky D., et al. Central nervous system side effects of p-adrenergic blocking agents with high and low lipid solubility. J. Cardiovasc Pharmacol. 1989;13(4):656-61.
  17. Brismar K., Mogensen L., Wetterberg L. Depressed melatonin secretion in patients with nightmares due to p-adrenoceptor blocking drugs. Acta Med Scand. 1987;221(2):155-58. doi: 10.1111/j.0954-6820.1987.tb01260.x.
  18. Betts T.A., Alford C. в-Blockers and sleep: a controlled trial. Eur J. Clin Pharmacol. 1985;28(1):65-8. doi: 10.1007/bf00543712.
  19. Нодель М.Р., Ковров Г. В. Нарушения сна при болезни Паркинсона: подходы к лечению и профилактике. Неврология, нейропсихиатрия, психосоматика. 2017;9(4):88-94. doi: 10.14412/2074-2711-2017-4-88-84.
  20. Morgenthaler T.I., Auerbach S., Casey K.R., et al. Position paper for the treatment of nightmare disorder in adults: an American Academy of Sleep Medicine position paper. J. Clin Sleep Med. 2018;14(6):1041-55. Doi: 10.5664/ jcsm.7178.
  21. Kitabayashi Y., Ueda H., Tsuchida H., et al. Donepezil-induced nightmares in mild cognitive impairment. Psychiatry Clin Neurosci. 2006;60(1):123-24. doi: 10.1111/j.1440-1819.2006.01474.x.
  22. Corbo J.M., Brown J.N., Moss J.M. Galan tamine-associated nightmares and anxiety. Consult Pharm. 2013;28(4):243-46. Doi: 10.4140/ TCPn.2013.243.
  23. Stahl S.M., Markowitz J.S., Papadopoulos G., et al. Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Curr Med Res Opin. 2004;20(4):517-24. doi: 10.1185/030079904125003214.
  24. Bengtsson C., lennartsson J., Lindquist O., et al. Sleep disturbances, nightmares and other possible central nervous disturbances in a population sample of women, with special reference to those on antihypertensive drugs. Eur J. Clin Pharmacol. 1980;17(3):173-77. doi: 10.1007/bf00561896.
  25. Cove-Smith J.R., Kirk C.A. CNS-related side-effects with metoprolol and atenolol. Eur J. Clin Pharmacol. 1985;28(1):69-72. Doi: 10.1007/ bf00543713.
  26. Due D.L., Giguere G.C., Plachetka J.R. Postmarketing comparison of labetalol and propranolol in hypertensive patients. Clin Ther. 1986;8(6):624-31.
  27. Davidov M.E., Glazer N., Wollam G., et al. Comparison of betaxolol, a new p1-adrenergic antagonist, to propranolol in the treatment of mild to moderate hypertension. Am J. Hypertens. 1988;1(3):206S-210S. Doi: 10.1093/ ajh/1.3.206S.
  28. Westerlund A. Central nervous system side-effects with hydrophilic and lipophilicв-Blockers. Eur J. Clin Pharmacol. 1985;28(1):73-6. doi: 10.1007/bf00543714.
  29. Kuriyama S. Bisoprolol-induced nightmares. J. Hum Hypertens. 1994;8(9):730.
  30. Boriani G., Biffi M., Strocchi E., et al. Nightmares and sleep disturbances with simvastatin and metoprolol. Ann Pharmacother. 2001;35(10):1292. doi: 10.1345/aph.1A079.
  31. Ahmed A.I.A., van Mierlo P., Jansen P. Sleep disorders, nightmares, depression and anxiety in an elderly patient treated with low-dose metoprolol. Gen Hosp Psychiatry. 2010;32(6):646.e5-e7. Doi: 10.1016/j. genhosppsych.2010.04.008.
  32. Haffner C.A., Smith B.S., Pepper C. Hallucinations as an adverse effect of angiotensin converting enzyme inhibition. Postgrad Med J. 199369(809):240. Doi: 10.1136/ pgmj.69.809.240.
  33. Lareb Database. [Internet]. Netherlands: Pharmacovigilance Centre Lareb. 2016 - [cited 2019 Sep 8]. Available from: https://www.lareb. nl/en/databank/
  34. Brockman M.M., Pharm D., Trewet C.B., et al. Lisinopril-induced nightmares. Pharmacotherapy. 2010;30(8):864. doi: 10.1592/phco.30.8.864.
  35. Gvilia I., Angara C., McGinty D., et al. Different neuronal populations of the rat median preoptic nucleus express c-fos during sleep and in response to hypertonic saline or angiotensin-II. J. Physiol. 2005;569(2):587-99. Doi: 10.1113/ jphysiol.2005.097212.
  36. Kastalli S., El A.S., Loueslati M.H., et al. Nightmares induced by valsartan. Therapie. 2006;61(1): 81-2. doi: 10.2515/therapie:2005069.
  37. Gregoor J.P. Atorvastatin may cause nightmares. Br Med J. 2006;332(7547):950. Doi: 10.1136/ bmj.332.7547.950.
  38. Cham S., Koslik H.J., Golomb B.A. Mood, personality, and behavior changes during treatment with statins: A case series. Drug Saf Case Rep. 2016;3(1):1-13. Doi: 10.1007/ s40800-015-0024-2.
  39. Lepkifker E., Dannon PN., Iancu I., et al. Nightmares related to fluoxetine treatment. Clin Neuropharmacol. 1995;18(1):90-4.
  40. Kobayashi T., Yamauchi M. A case of serial nightmares and oneiroid state under paroxetine for senile depression. Psychogeriatrics. 2012;12(1):54-7. doi: 10.1111/j.1479-8301.2011.00382.x.
  41. McRae A.L., Brady K.T., Mellman T.A., et al. Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depress Anxiety. 2004;19(3):190-96. doi: 10.1002/da.20008.
  42. Arora G., Sandhu G., Fleser C. Citalopram and nightmares. J. Neuropsychiatry Clin Neurosci. 2012;24(2):E43. doi: 10.1176/appi. neuropsych.11040096.
  43. Joyce P.R., Walshe J. Nightmares during phenelzine withdrawal. J. Clin Psychopharmacol. 1983;3(2):121.
  44. Palladino A. Jr. Adverse reactions to abrupt discontinuation of phenelzine. J. Clin Psychopharmacol. 1983;3(3):206-7.
  45. Akindele M.O., Evans J.I., Oswald I. Monoamine oxidase inhibitors, sleep and mood. Electroencephalogr Clin Neurophysiol. 1970;29(1):4 7-56. doi: 10.1016/0013-4694(70)90078-7.
  46. Hogben G.L., Cornfield R.B. Treatment of traumatic war neurosis with phenelzine. Arch Gen Psychiatry. 1981;38(4):440-45. doi: 10.1001/archpsyc.1981.01780290074008.
  47. Lerer B., Bleich A., Kotler M., et al. Posttraumatic stress disorder in Israeli combat veterans: effect of phenelzine treatment. Arch Gen Psychiatry. 1987;44(11):976-81. Doi: 10.1001/ archpsyc.1987.01800230056010.
  48. Schredl M., Berger M., Riemann D. The effect of trimipramine on dream recall and dream emotions in depressive outpatients. Psychiatry Res. 2009;167(3):279-86. Doi: 10.1016/j. psychres.2008.03.002.
  49. Whitman R.M., Pierce C.M., Maas J.W., et al. Drugs and dreams II: Imipramine and prochlorperazine. Compr Psychiatry. 1961;2(4):219-26. doi: 10.1016/s0010-440x(61)80014-x.
  50. Flemenbaum A. Pavor nocturnus: a complication of single daily tricyclic or neuroleptic dosage. Am J Psychiatry. 1976;133(5):570-72. doi: 10.1176/ajp.133.5.570.
  51. Strayhorn J.M., Nash J.L. Frightening dreams and dosage schedule of tricyclic and neuroleptic drugs. J NervMent Dis. 1978;166(12):878-80. doi: 10.1097/00005053-197812000-00008.
  52. Lewis S.A, Oswald I. Overdose of tricyclic anti-depressants and deductions concerning their cerebral action. Br J Psychiatry. 1969;115(529):1403-10. Doi: 10.1192/ bjp.115.529.1403.
  53. Dilsaver S.C., Feinberg M., Greden J.F Antidepressant withdrawal symptoms treated with anticholinergic agents. Am J Psychiatry. 1983;140(2):249-51. Doi:10.1176/ ajp.140.2.249.
  54. Boisvert D., Chouinard G. Rebound cardiac arrhythmia after withdrawal from imipramine: A case report. Am J Psychiatry. 1981;138(7):985 86. doi: 10.1176/ajp.138.7.985
  55. Kantor S.J. Depression: when is psychotherapy not enough? Psychiatr Clin North Am. 1990;13(2):241-54.
  56. Boehnlein J.K., Kinzie J.D., Ben R., et al. One-year follow-up study of posttraumatic stress disorder among survivors of Cambodian concentration camps. Am J Psychiatry. 1985;142(8):956-59. doi: 10.1176/ajp.142.8.956.
  57. Mathews M., Basil B., Evcimen H., et al. Mirtazapine-Induced Nightmares. Prim Care Companion J Clin Psychiatry. 2006;8(5):311. doi: 10.4088/pcc.v08n0510b.
  58. Dang A, Garg G., Rataboli PV Mirtazapine induced nightmares in an adult male. Br J Clin Pharmacol. 2009;67(1):135-36. doi: 10.1111/j.1365-2125.2008.03305.x.
  59. Felthous A.R., Wenger PJ., Hoevet R. Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment. Pharmacotherapy. 2010;30(4):145e-50e. doi: 10.1592/phco.30.4.423.
  60. Menon V, Madhavapuri P Low-Dose mirtazapine-induced nightmares necessitating its discontinuation in a young adult female. J Pharmacol Pharmacother. 2017;8(4):182-84. doi: 10.4103/jpp.JPP_116_17.
  61. Australian Adverse Drug Reactions Advisory Committee (ADRAC). Convulsions and blood dyscrasias with mirtazapine. Aust Adverse Drug React Bull. 2003;22:18-9.
  62. Balon R. Bupropion and nightmares. Am J. Psychiatry 1996;153(4):579-80. doi: 10.1176/ajp.153.4.579b.
  63. Adelman L.C., Adelman J.U., Von Seggern R., et al. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache. 2000;40(7):572-80. doi: 10.1046/j.1526-4610.2000.00089.x.
  64. Lam S.P., Zhang J., Tsoh J., et al. REM sleep behavior disorder in psychiatric populations. J. Clin Psychiatry 2010;71(8):1101-103. doi: 10.4088/JCPl05877gry.
  65. Kumar S., Bhatia M., Behari M. Sleep disorders in Parkinson's disease. Mov Disord. 2002;17(4):775-81. Doi: 10.1002/ mds.10167.
  66. Buongiorno M., Antonelli F., Camara A., et al. long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. ParkRelat Disord. 2015;21(8):871-76. doi: 10.1016/j.parkreldis.2015.05.014.
  67. Alvi M.Y. Unusual Effect of Fenfluramine. Br Med J. 1969;4(5677):237. Doi: 10.1136/ bmj.4.5677.237-c.
  68. Hooper A.C. Fenfluramine and Dreaming. Br Med J. 1971;3(5769):305. Doi: 10.1136/ bmj.3.5769.305-b.
  69. Mullen A., Wilson C.W., Wilson B.P. Dreaming, fenfluramine, and vitamin C. Br Med J. 1977;1(6053):70-2. Doi: 10.1136/ bmj.1.6053.70.
  70. Oswald I. Sleep, dreaming and drugs. Proc R. Soc Med. 1969;62(2):151-53.
  71. Allain H., Delahaye C., Le Coz F., et al. Postmarketing surveillance of zopiclone in insomnia: Analysis of 20,513 cases. Sleep. 1991;14(5):408-13. Doi: 10.1093/ sleep/14.5.408.
  72. Gaillard J.M., Phelippeau M. Benzodiazepine induced modifications of dream content: The effect of flunitrazepam. Neuropsychobiology. 1976;2(1):37-44. doi: 10.1159/000117527.
  73. Gaillard J.M., Phelippeau M. Change in the mental contents in the paradoxical stage and in stage 2 under the effects of a benzodiazepine, flunitrazepam. Encephale. 1977;3(1):35-47.
  74. McGarry PM. A double-blind study of diazepam, droperidol, and meperidine as premedication in children. Can Anaesth Soc J. 1970;17(2):157-65. doi: 10.1007/bf03004666.
  75. Burdine W.E. Diazepam in a general psychiatric practice. Am J Psychiatry. 1964;121(6):589 92. doi: 10.1176/ajp.121.6.589
  76. Hollister L.E., Conley F.K., Britt R.H., et al. Long-term use of diazepam. JAMA. 1981;246(14):1568-70.
  77. Girwood R.H. Nitrazepam nightmares. BMJ. 1973;1(5849):353. Doi: 10.1136/ bmj.1.5849.353.
  78. Ellingsen PA. Double-blind trial of triazolam 0.5 mg vs. nitrazepam 5 mg in outpatients. Acta Psychiatr Scand. 1983;67(3):154-58. doi: 10.1111/j.1600-0447.1983.tb00336.x.
  79. Schacht P., Arcieri G., Hullmann R. Safety of oral ciprofloxacin. An update based on clinical trial results. Am J. Med. 1989;87(5A):98S-102S. doi: 10.1016/0002-9343(89)90033-8.
  80. Bowie W.R., Willetts V., Jewesson PJ. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother. 1989;33(10):1778-82. doi: 10.1128/aac.33.10.1778.
  81. Dang A., Kamat R., Padmanabh R. Ciprofloxacin induced nightmares in an adult patient. Indian J. Psychiatry. 2008;50(4):305-6. doi: 10.4103/0019-5545.44757.
  82. Dey S.K. Nightmare due to ciprofloxacin in young patients. Indian Pediatr. 1995;32(8):918-20.
  83. Rawi S.M., Mourad I.M., Arafa N.M.S., et al. Effect of ciprofloxacin and levofloxacin on some oxidative stress parameters in brain regions of male albino rats. African J. Pharm Pharmacol. 2011;5(16):1888-97. Doi: 10.5897/ AJPP11.417.
  84. Williams N.R. Erythromycin: A case of nightmares. Br Med J. (Clin Res Ed). 1988;296(6616):214. doi: 10.1136/bmj.296.6616.214-d.
  85. Black R.J., Dawson T.A.J. Drug points: Erythromycin and nightmares. BMJ. 1988;296(6628):1070.
  86. M0ller M.E., Aziz Q., Juel J. Erythromycin induced nightmares. J. Neurogastroenterol Motil. 2016;22(3):539-40. Doi: 10.5056/ jnm16046.
  87. Chen J.L., Brocavich J.M., Lin A.Y. Psychiatric disturbances associated with ganciclovir therapy Ann Pharmacother. 1992;26(2):193-95. doi: 10.1177/106002809202600210.
  88. Soler Palacin P., Aramburo A., Moraga FA., et al. Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient. Pediatr Infect Dis J. 2006;25(4):382. doi: 10.1097/01. inf.0000207467.39022.cc.
  89. Colebunders R., Hilbrands R., De Roo A., et al. Neuropsychiatric reaction induced by abacavir. Am J. Med. 2002;113(7):616. Doi: 10.1016/ s0002-9343(02)01259-7.
  90. Abers M.S., Shandera W.X., KassJ.S. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs. 2014;28(2):131-45. doi: 10.1007/s40263-013-0132-4.
  91. Couzigou C., Seang S., Morand-Joubert L., et al. Efficacy of etravirine for treatment of acute HIV meningoencephalitis. Clin Infect Dis. 2009;48(6):e62-5. doi: 10.1086/597109.
  92. Allavena C., Le Moal G., Michau C., et al. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: A report of nine cases. Antivir Ther. 2006;11(2):263-65.
  93. Teppler H., Brown D.D., Leavitt R.Y., et al. Long-term safety from the raltegravir clinical development program. Curr HIV Res. 2011;9(1):40-53.
  94. Flisberg P., Rudin A., Linner R., et al. Pain relief and safety after major surgery A prospective study of epidural and intravenous analgesia in 2696 patients. Acta Anaesthesiol Scand. 2003;47(4):457-65. doi: 10.1034/j.1399-6576.2003.00104.x.
  95. Glare P, Walsh D., Sheehan D. The Adverse Effects of Morphine : Dosing for Chronic Cancer Pain. Am J Hosp Palliat Med. 2006;23(3):229 35. doi: 10.1177/1049909106289068
  96. Chao J. Retrospective analysis of Kadian (morphine sulfate sustained-release capsules) in patients with chronic, nonmalignant pain. Pain Med. 2005;6(3):262-65. Doi:10.1111/ j.1526-4637.2005.05033.x.
  97. Kalso E., Heiskanen T., Rantio M., et al. Epidural and subcutaneous morphine in the management of cancer pain: A double-blind corss-over study. Pain. 1996;67(2-3):443-49. doi: 10.1016/0304-3959(96)03161-2.
  98. Njee T.B., Irthum B., Roussel P., et al. Intrathecal morphine infusion for chronic non-malignant pain: A multiple center retrospective survey. Neuromodulation. 2004;7(4):249-59. doi: 10.1111/j.1094-7159.2004.04210.x.
  99. Ross J.R., Riley J., Taegetmeyer A.B., et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer. 2008;112(6):1390-403. Doi: 10.1002/ cncr.23292.
  100. Riley J., Branford R., Droney J., et al. Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial. J. Pain Symptom Manage. 2015;49(2):161-72. doi: 10.1016/j.jpainsymman.2014.05.021.
  101. Onofrio S., Vartan C.M., Nazario M., et al. The use of transdermal buprenorphine in complex regional pain syndrome: a report of two cases. J Pain Palliat Care Pharmacother. 2016;30(2):124-27. Doi: 10.3 109/15360288.201 6.1173756
  102. Mucci-LoRusso P., Berman B.S., Silberstein PT., et al. Controlled-release oxycodone compared with controlled release morphine in the treatment of cancer pain. Eur J. Pain. 1998;2(3):239-49.
  103. Wirz S., Wartenberg H.C., Wittmann M.T.S., et al. Post-operative pain therapy with controlled release oxycodone or controlled release tramadol following orthopedic surgery: A prospective, randomized, double-blind investigation. Pain Clin. 2005;17(4):367-76. doi: 10.1163/156856905774482733.
  104. Elia N., Tramer M.R. Ketamine and postoperative pain - A quantitative systematic review of randomised trials. Pain. 2005;113(1-2):61 70. doi: 10.1016/j.pain.2004.09.036
  105. Laskowski K., Stirling A., McKay W.P., et al. A systematic review of intravenous ketamine for postoperative analgesia. Can J. Anesth. 2011;58(10):911-23. doi: 10.1007/s12630-011-9560-0.
  106. Kiefer R.T., Rohr P., Ploppa A., et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: An open-label phase II study. Pain Med. 2008;9(8):1173-201. doi: 10.1111/j.1526-4637.2007.00402.x.
  107. Blagrove M., Morgan C.J., Curran H.V., et al. The incidence of unpleasant dreams after subanaesthetic ketamine. Psychopharmacology (Berl). 2009;203(1):109-20. Doi: 10.1007/ s00213-008-1377-3.
  108. Hayashi Y., Morinaga S., Zhang J., et al. BK channels in microglia are required for morphine-induced hyperalgesia. Nat Commun. 2016;31(7):11697. Doi: 10.1038/ ncomms11697.
  109. Kim S.H., Price M.T., Olney J.W., et al. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and a2-adrenergic agonists. Mol Psychiatry 1999;4(4):344-52.
  110. Bakht F.R., Miller L.G. Naproxen-Associated Nightmares. South Med J. 1991;84(10):1271 73. doi: 10.1097/00007611-199110000 00027
  111. VigiBase. [Internet]. Uppsala: Uppsala Monitoring Centre. 1968 - [cited 2019 Sep 8]. Available from: http://www.vigiaccess.org/
  112. Hamner M.B., Brodrick P.S., Labbate L.A. Gabapentin in PTSD: A retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001;13(3):141-46.
  113. Berlant J., van Kammen D.P. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report. J. Clin Psychiatry. 2002;63(1):15-20. doi: 10.4088/jcp. v63n0104.
  114. Berlant J.L. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry. 2004;4:1-6. doi: 10.1186/1471-244X-4-24.
  115. Alderman C.P, McCarthy L.C., Condon J.T., et al. Topiramate in combat-related posttraumatic stress disorder. Ann Pharmacother. 2009;43(4):635 41. doi: 10.1345/aph.1L578
  116. Tucker P., Trautman R.P., Wyatt D.B.,. et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: A randomized, double-blind, placebo-controlled study. J. Clin Psychiatry. 2007;68(2):201-6. Doi: 10.4088/ jcp.v68n0204.
  117. Turner R., Elson E. Sleep disorders. Steroids cause sleep disturbance. BMJ. 1993;29;306(6890):1477-78. Doi: 10.1136/ bmj.306.6890.1477-d.
  118. Clifton D., Ross M., O’Callaghan C. Psychiatric sequelae of corticosteroid use in hematology in Australia: A qualitative study. Nurs Heal Sci. 2018;20(1):125-31. Doi: 10.1111/ nhs.12395.
  119. Pokladnikova J., Meyboom R.H.B., Vlcek J., et al. Intranasally administered corticosteroids and neuropsychiatrie disturbances: A review of the International Pharmacovigilance Programme of the World Health Organization. Ann Allergy, Asthma Immunol. 2008;101(1):67-73. doi: 10.1016/S1081-1206(10)60837-X.
  120. Hilty D., Young J.S., Bourgeois J.A., et al. Algorithms for the assessment and management of insomnia in primary care. Patient Prefer Adherence. 2009;3:9-20.
  121. Wallerstedt S.M., Brunlof G., Sundstrom A., et al. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf. 2009;18(9):858-64. Doi: 10.1002/ pds.1794.
  122. Cereza G., Garcia Dolade N., Laporte J.R. Nightmares induced by montelukast in children and adults. Eur Respir J. 2012;40(6):1574-75. doi: 10.1183/09031936.00092812.
  123. Ward D.E., Camm A.J., Spurrell R.A. Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. Br Heart J. 1980;44(1):91-5. Doi: 10.1136/ hrt.44.1.91.
  124. Haffajee C.I., Love J.C., Alpert J.S., et al. Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: Dosage experience. Am Heart J. 1983;106(4 Pt 2):935-43. doi: 10.1016/0002-8703(83)90019-4.
  125. Ringqvist A., Bech P, Glenth0j B., et al. Acute and long-term psychiatric side effects of mefloquine: A follow-up on Danish adverse event reports. Travel Med Infect Dis. 2015;13(1):80-8. doi: 10.1016/j.tmaid.2014.10.021.
  126. Ritchie C.E., Block J., Nevin R.L. Psychiatric side effects of mefloquine: Applications to forensic psychiatry. J. Am Acad Psychiatry Law. 2013;41(2):224-35.
  127. Peterson A.L., Seegmiller R.A., Schindler L.S. Severe neuropsychiatric reaction in a deployed military member after prophylactic mefloquine. Case Rep Psychiatry. 2011;2011:1-4. doi: 10.1155/2011/350417.
  128. Maertens C., Wei L., Droogmans G., et al. Inhibition of volume-regulated and calcium-activated chloride channels by the antimalarial mefloquine. J. Pharmacol Exp Ther. 2000;295(1):29-36.
  129. Gribble F.M., Davis T.M., Higham C.E., et al. The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. Br J. Pharmacol. 2000;131(4):756-60. Doi: 10.1038/ sj.bjp.0703638.
  130. Weiss S.M., Benwell K., Cliffe I.A., et al. Discovery of nonxanthine adenosine A2Areceptor antagonists for the treatment of Parkinson's disease. Neurology. 2003;61(11 Suppl. 6):S101-6. doi: 10.1212/01. wnl.0000095581.20961.7d.
  131. Milatovic D., Jenkins J.W., Hood J.E., et al. Mefloquine neurotoxicity is mediated by nonreceptor tyrosine kinase. Neurotoxicology]. 2011;32(5):578-85. Doi: 10.1016/j. neuro.2011.01.001.
  132. Savage R.L., Zekarias A., Caduff-Janosa P. Varenicline and abnormal sleep related events. Sleep. 2015;38(5):833-37. Doi: 10.5665/ sleep.4(586.
  133. Harrison-Woolrych M., Ashton J. Psychiatric adverse events associated with varenicline: An intensive postmarketing prospective cohort study in New Zealand. Drug Saf. 2011;34(9):763-72. doi: 10.2165/11594450-000000000-00000.
  134. Fouz-Roson N., Montemayor-Rubio T., Almadana-Pacheco V., et al. Effect of 0,5 mg versus 1 mg varenicline for smoking cessation: a randomized controlled trial. Addiction. 2017;112(9):1610-19. Doi: 10.1111/ add.13855.
  135. Tulloch H.E., Pipe A.L., Els C., et al. Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: A randomized controlled trial. BMC Med. 2016;14(1):1-10. Doi: 10.1186/ s12916-016-0626-2.
  136. Gonzales D., Hajek P., Pliamm L., et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: A randomized, placebo-controlled trial. Clin Pharmacol Ther. 2014;96(3):390-96. doi: 10.1038/clpt.2014.124.
  137. Kasliwal R., Wilton L.V., Shakir S.A. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf. 2009;32(6):499-507. doi: 10.2165/00002018-200932060-00006.
  138. Williams K.E., Reeves K.R., Billing C.B. et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23(4):793-801. doi: 10.1185/030079907X182185.
  139. Thomas K.H., Martin R.M., Knipe D.W., et al. Risk of neuropsychiatric adverse events associated with varenicline: Systematic review and metaanalysis. BMJ. 2015;350:h1109. Doi: 10.1136/ bmj.h1109.
  140. Eisenberg M.J., Windle S.B., Roy N., et al. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. 2015;133(1):21-31. Doi: 10.1161/ CIRCULATIONAHA.115.019634.
  141. Baker T.B., Piper M.E., Stein J.H., et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: A randomized clinical trial. JAMA. 2016;315(4):371-79. Doi: 10.1001/ jama.2015.19284.
  142. Tomioka H., Wada T., Yamazoe M., et al. Ten-year experience of smoking cessation in a single center in Japan. Respir Investig. 2019;57(4):380-87. doi: 10.1016/j.resinv.2019.01.007.
  143. Chang PH., Chiang C.H., Ho W.C., et al. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: A systematic review and meta-analysis of randomized controlled trials. BMC Public Health. 2015;15(1):1-8. doi: 10.1186/s12889-015-2055-0.
  144. Funk W., Jakob W., Riedl T., et al. Oral preanaesthetic medication for children: Doubleblind randomized study of a combination of midazolam and ketamine vs midazolam or ketamine alone. Br J Anaesth. 2000;84(3):335 40. doi: 10.1093/oxfordjournals.bja.a013435
  145. Alderson P.J., Lerman J. Oral premedication for paediatric ambulatory anaesthesia: a comparison of midazolam and ketamine. Can J Anaesth. 1994;41(3):221-26. Doi: 10.1007/ BF03009834
  146. Liu D., Ahmet A., Ward L., et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma Clin Immunol. 2013;9(1):30. doi: 10.1186/1710-1492-9-30

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2019

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies